Oppenheimer analyst Hartaj Singh maintained a Buy rating on Gain Therapeutics (GANX – Research Report) today and set a price target of $9.00. The company’s shares closed yesterday at $3.17.
Singh covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Vertex Pharmaceuticals, and Sarepta Therapeutics. According to TipRanks, Singh has an average return of 9.5% and a 44.10% success rate on recommended stocks.
Currently, the analyst consensus on Gain Therapeutics is a Strong Buy with an average price target of $9.50.
Based on Gain Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $4.72 million. In comparison, last year the company had a GAAP net loss of $4.67 million
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GANX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Gain Therapeutics (GANX) Company Description:
Gain Therapeutics Inc is a development-stage biotechnology company developing novel therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders (LSDs), including rare genetic diseases and neurological disorders. Its pipeline includes the GLB1 gene, GBA1 gene, IDUA gene, and GALC gene.
Read More on GANX:
- Gain Therapeutics Welcomes New CFO Gene Mack
- Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
- Gain Therapeutics appoints Gene Mack as CFO
- Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
- Gain Therapeutics appoints Jonas Hannestad as CMO
